Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZSNASDAQ:BCABNASDAQ:CALCNASDAQ:FGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.41$3.50$3.96▼$12.00$6.11M1.557,305 shs284 shsBCABBioAtla$0.38-4.5%$0.43$0.24▼$2.53$22.20M0.91915,519 shs1.33 million shsCALCCalciMedica$1.62+2.5%$1.73$1.42▼$5.97$22.62M1.2441,880 shs21,507 shsFGENFibroGen$5.69+8.4%$7.21$4.50▼$38.25$22.99M0.7476,019 shs33,072 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris-0.58%+1.79%-6.58%+25.60%-22.68%BCABBioAtla-4.45%+1.31%-27.31%+35.62%-73.43%CALCCalciMedica+2.47%+13.22%-0.67%-11.04%-62.00%FGENFibroGen+8.38%+7.36%-24.46%-18.71%-67.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/ABCABBioAtla2.581 of 5 stars3.32.00.00.02.42.50.6CALCCalciMedica3.2796 of 5 stars3.54.00.00.02.63.30.0FGENFibroGen4.7203 of 5 stars3.33.00.04.74.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/ABCABBioAtla 2.50Moderate Buy$5.001,215.79% UpsideCALCCalciMedica 3.00Buy$18.001,011.80% UpsideFGENFibroGen 2.50Moderate Buy$250.004,293.67% UpsideCurrent Analyst Ratings BreakdownLatest AEZS, BCAB, FGEN, and CALC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$250.00 ➝ $250.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.58N/AN/A$14.99 per share0.23BCABBioAtla$11M2.02N/AN/A$0.25 per share1.52CALCCalciMedicaN/AN/AN/AN/A$1.07 per shareN/AFGENFibroGen$29.62M0.78N/AN/A($50.89) per share-0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)BCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)CALCCalciMedica-$13.70M-$1.56N/AN/AN/AN/A-171.81%-100.43%8/11/2025 (Estimated)FGENFibroGen-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)Latest AEZS, BCAB, FGEN, and CALC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CALCCalciMedica-$0.43-$0.36+$0.07-$0.36N/AN/A5/12/2025Q1 2025FGENFibroGen$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/ABCABBioAtlaN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93BCABBioAtlaN/A2.352.35CALCCalciMedica0.795.665.66FGENFibroGenN/A2.021.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%BCABBioAtla77.23%CALCCalciMedicaN/AFGENFibroGen72.71%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%BCABBioAtla11.50%CALCCalciMedica41.55%FGENFibroGen3.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataBCABBioAtla6058.42 million51.70 millionOptionableCALCCalciMedica3013.97 million8.17 millionNo DataFGENFibroGen5704.04 million3.92 millionOptionableAEZS, BCAB, FGEN, and CALC HeadlinesRecent News About These CompaniesFibroGen, Inc (NASDAQ:FGEN) Director James A. Schoeneck Acquires 23,567 SharesJuly 3 at 7:09 AM | insidertrades.comFibroGen Inc.June 24, 2025 | marketwatch.comFibroGen (NASDAQ:FGEN) Trading Down 6.7% - What's Next?June 17, 2025 | marketbeat.comFibroGen To Implement 1-for-25 Reverse Stock SplitJune 14, 2025 | nasdaq.comFibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025June 14, 2025 | nasdaq.comFibroGen Enters Relicensing Agreement with HiFiBiOJune 13, 2025 | marketwatch.comFibroGen Announces 1-for-25 Reverse Stock SplitJune 12, 2025 | globenewswire.comFibroGen, Inc. Appoints Dr. Michael Kauffman to Board of DirectorsJune 9, 2025 | quiverquant.comQFibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of DirectorsJune 9, 2025 | globenewswire.comFibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipelineMay 13, 2025 | msn.comFibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comFibroGen, Inc.: FibroGen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deFibroGen, Inc. (FGEN) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comFibroGen (FGEN) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comFibroGen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comA Preview Of FibroGen's EarningsMay 10, 2025 | benzinga.comDuchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)May 8, 2025 | globenewswire.comFibroGen, Inc. to Announce Q1 2025 Financial Results and Host Conference Call on May 12May 7, 2025 | nasdaq.comFibroGen to Report First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comWilliam Blair Keeps Their Hold Rating on FibroGen (FGEN)April 2, 2025 | markets.businessinsider.comFibroGen to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEZS, BCAB, FGEN, and CALC Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.41 0.00 (0.00%) As of 07/3/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.BioAtla NASDAQ:BCAB$0.38 -0.02 (-4.45%) Closing price 07/3/2025 03:06 PM EasternExtended Trading$0.38 0.00 (0.00%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.CalciMedica NASDAQ:CALC$1.62 +0.04 (+2.47%) As of 07/3/2025 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.FibroGen NASDAQ:FGEN$5.69 +0.44 (+8.38%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$5.61 -0.08 (-1.41%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
